Guidant makes EU Drug-eluting stent (DES) debutwith Xience
This article was originally published in Clinica
Just days after agreeing to be acquired by Boston Scientific, Guidant has gained European market clearance for its drug-eluting stent (DES) for treating coronary artery blockages.
You may also be interested in...
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.